Vaxxas, Inc.

Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will be fundamental to help the world in rethinking what`s possible with vaccines. Vaxxas` approach which has been validated in human clinical studies can enhance the efficiency and effectiveness of a vaccine`s immune response. The company uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and transportation - easing the resource and logistics burden of maintaining the vaccine `cold chain`.